MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
Reporting to the Executive Director of FP&A (based in US), the Senior Director, FP&A – International will lead and own the financial planning and analysis function for Mirum’s International Commercial Operations. Based in Zug, this role serves as the primary finance partner to International leadership, with full accountability for financial performance, planning, and strategic decision support across Europe and expanding global markets.
This individual will play a critical role in building and scaling the international finance capability to support the commercialization of LIVMARLI and future pipeline assets. As a core member of the International leadership team, the role will drive financial visibility, inform strategic decisions, and ensure alignment between regional execution and global corporate objectives.
This position combines strategic leadership with hands-on execution in a dynamic, growth-stage biotech environment and requires close collaboration with Commercial, Market Access, Supply Chain, R&D, Legal, Compliance, HR, and global Finance teams.
JOB FUNCTIONS/RESPONSIBILITIES
International Commercial Finance Leadership
- Own and lead FP&A for International Commercial Operations, with full accountability for regional P&L performance
- Serve as the primary finance partner to International leadership, influencing strategy, investment decisions, and operational execution
- Act as a bridge between International markets and US headquarters, ensuring alignment with global financial goals and expectations
- Build and evolve the international FP&A capability, including processes, tools, and team structure over time
Planning, Forecasting & Performance Management
- Lead the annual planning process, long-range planning, and ongoing forecasting cycles for International markets
- Partner cross-functionally to develop robust, data-driven forecasts, challenging assumptions and identifying risks and opportunities
- Drive monthly and quarterly business reviews, delivering clear insights into performance drivers and actionable recommendations
- Ensure timely and accurate financial reporting, translating results into meaningful business insights for leadership
Strategic Decision Support & Growth
- Lead scenario planning and financial modeling to support key business decisions, including market expansion, product launches, and resource allocation
- Evaluate investment opportunities through ROI analysis, supporting prioritization of high-impact initiatives
- Partner with Commercial and regional teams to optimize resource deployment and maximize return on investment
- Support launch planning for new products and geographic expansion, including financial modeling and risk assessment
Pricing, Market Access & Profitability
- Partner with Market Access to support pricing strategy and governance, balancing access considerations with profitability objectives
- Conduct pricing and sensitivity analyses to inform key decisions across markets
- Develop a deep understanding of market dynamics, including competitive landscape, reimbursement environments, and access constraints
- Identify and drive margin improvement opportunities through pricing, cost optimization, and strategic trade-offs
Operational Excellence & Process Improvement
- Drive enhancements in financial planning processes, data quality, and reporting capabilities
- Support the implementation and optimization of FP&A systems and tools to enable scalable growth
- Establish and standardize best practices across markets while accommodating local market nuances
- Navigate financial complexities across multiple jurisdictions, including FX exposure and evolving market conditions
Leadership & Stakeholder Management
- Influence and collaborate with senior stakeholders across geographies and functions
- Present financial insights and recommendations to executive leadership and global finance teams
- Foster strong partnerships across International Commercial, ensuring finance is embedded in decision-making
- Contribute to building a high-performance, collaborative, and accountable culture within the organization
QUALIFICATIONS
Education /Experience:
- 12–15+ years of progressive experience in FP&A or finance, with significant exposure to global or international operations
- Prior experience in biotech, pharmaceuticals, or life sciences strongly preferred, particularly in commercial-stage environments
- Demonstrated experience supporting international markets, including product launches and market expansion
- Strong financial modeling, forecasting, and strategic planning capabilities
- Proven ability to influence senior stakeholders and operate as a strategic business partner
- Experience working in complex, multi-country environments with an understanding of market access and pricing dynamics
- Ability to thrive in a fast-paced, high-growth environment with evolving priorities
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Skills Required
- 12-15+ years of progressive experience in FP&A or finance
- Experience in biotech, pharmaceuticals, or life sciences
- Strong financial modeling, forecasting, and strategic planning capabilities
- Ability to influence senior stakeholders
Mirum Pharmaceuticals Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Mirum Pharmaceuticals and has not been reviewed or approved by Mirum Pharmaceuticals.
-
Equity Value & Accessibility — Equity grants to new hires and an employee stock purchase plan make ownership more accessible and can boost total rewards when performance is strong. Public disclosures highlight frequent option/RSU inducements.
-
Healthcare Strength — Comprehensive medical, dental, and vision coverage is employer-paid for employees, with added life, disability, and EAP support. This combination reduces financial burden and enhances overall wellbeing.
-
Leave & Time Off Breadth — A broad time-off program includes multiple paid company holidays, a year-end shutdown, accrued vacation, and paid parental leave. This breadth provides additional rest periods beyond standard vacation.
Mirum Pharmaceuticals Insights
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
